Abstract
Genomic studies revealed two main components in the genetic architecture of schizophrenia, one constituted by common variants determining a distributed polygenic effect and one represented by a large number of heterogeneous rare and highly disruptive mutations. These gene modifications often affect neural transmission and different studies proved an involvement of metabotropic glutamate receptors in schizophrenia phenotype. Through the combination of literature information with genomic data from public repositories, we analyzed the current knowledge on the involvement of genetic variations of the human metabotropic glutamate receptors in schizophrenia and related endophenotypes. Despite the analysis did not reveal a definitive connection, different suggestive associations have been identified and in particular a relevant role has emerged for GRM3 in affecting specific schizophrenia endophenotypes. This supports the hypothesis that these receptors are directly involved in schizophrenia disorder.
Keywords: Metabotropic glutamate receptors, schizophrenia, antipsychotic drugs, gene variants, omics data, bioinformatics.
Graphical Abstract
Current Neuropharmacology
Title:The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia
Volume: 14 Issue: 5
Author(s): Carlo Maj, Alessandra Minelli, Edoardo Giacopuzzi, Emilio Sacchetti and Massimo Gennarelli
Affiliation:
Keywords: Metabotropic glutamate receptors, schizophrenia, antipsychotic drugs, gene variants, omics data, bioinformatics.
Abstract: Genomic studies revealed two main components in the genetic architecture of schizophrenia, one constituted by common variants determining a distributed polygenic effect and one represented by a large number of heterogeneous rare and highly disruptive mutations. These gene modifications often affect neural transmission and different studies proved an involvement of metabotropic glutamate receptors in schizophrenia phenotype. Through the combination of literature information with genomic data from public repositories, we analyzed the current knowledge on the involvement of genetic variations of the human metabotropic glutamate receptors in schizophrenia and related endophenotypes. Despite the analysis did not reveal a definitive connection, different suggestive associations have been identified and in particular a relevant role has emerged for GRM3 in affecting specific schizophrenia endophenotypes. This supports the hypothesis that these receptors are directly involved in schizophrenia disorder.
Export Options
About this article
Cite this article as:
Maj Carlo, Minelli Alessandra, Giacopuzzi Edoardo, Sacchetti Emilio and Gennarelli Massimo, The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia, Current Neuropharmacology 2016; 14 (5) . https://dx.doi.org/10.2174/1570159X13666150514232745
DOI https://dx.doi.org/10.2174/1570159X13666150514232745 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Silver Nanoparticles: Synthesis, Antimicrobial Coatings, and Applications for Medical Devices
Recent Patents on Materials Science Organotypic Cultures as Tool to Test Long-Term Effects of Chemicals on the Nervous System
Current Medicinal Chemistry Human Amniotic Fluid Stem Cells as an Attractive Tool for Clinical Applications
Current Stem Cell Research & Therapy A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4
Current Drug Metabolism Serum β-Amyloid Peptide Levels Spike in the Early Stage of Alzheimer- Like Plaque Pathology in an APP/PS1 Double Transgenic Mouse Model
Current Alzheimer Research Cholinesterases and Cholinesterase Inhibitors
Current Enzyme Inhibition Editorial: Optimizing Chronic Heart Failure Care Beyond Randomised Controlled Trials – What are the problem areas and potential solutions?
Current Cardiology Reviews Dopamine Pharmacological Agents in Resistant-OCD
Current Psychopharmacology Editorial [Hot Topic: Analgesic Drug Discovery: Promising Future (Guest Editor: Anindya Bhattacharya)]
Current Pharmaceutical Biotechnology (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer’s Disease
Current Alzheimer Research Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design Editorial (Thematic Issue: Current Status and Progress of Radiopharmaceuticals for Molecular Imaging and Targeted Therapy)
Current Medicinal Chemistry Depression and Suicidal Behavior in Medical Students: A Systematic Review
Current Psychiatry Reviews Brain Metabolism of Ethanol and Alcoholism: An Update
Current Drug Metabolism Maintenance CBT in Preventing Relapse in Patients on SSRI Continuation
Current Psychopharmacology Menopausal Transition and Chronic Diseases
Current Women`s Health Reviews Author Index To Volume 6
Central Nervous System Agents in Medicinal Chemistry Acceptability and Results of Dementia Screening Among Older Adults in the United States
Current Alzheimer Research